AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) ...

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

This perioperative approach with Imfinzi underscores our commitment to moving into earlier stages of cancer where novel ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab) with standard-of-care fluorouracil, leucovorin, oxaliplatin ...